Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Merck
AstraZeneca
McKinsey

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,132,570

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,132,570 protect, and when does it expire?

Patent 7,132,570 protects NUVIGIL and is included in one NDA.

Protection for NUVIGIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in twenty-nine countries.

Summary for Patent: 7,132,570
Title:Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Abstract:The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.
Inventor(s): Neckebrock; Olivier (Ponteau Combault, FR), Leproust; Pierre (Creteil, FR)
Assignee: Cephalon France (Maisons-Alfort Cedex, FR)
Application Number:10/539,918
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,132,570
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 7,132,570

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-002 Mar 26, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-003 Jun 15, 2007 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-004 Jun 15, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,132,570

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 16412Dec 20, 2002
PCT Information
PCT FiledDecember 18, 2003PCT Application Number:PCT/FR03/03799
PCT Publication Date:July 22, 2004PCT Publication Number: WO20/04/060858

International Family Members for US Patent 7,132,570

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 042546   Start Trial
Australia 2003299349   Start Trial
Australia 2010212462   Start Trial
Brazil 0316916   Start Trial
Canada 2510096   Start Trial
Canada 2724305   Start Trial
Chile 2016002640   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Medtronic
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.